🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

MINIMISING SURGERY AND DRUG INTERVENTION Three studies led by researchers at MIA are paving the way for less surgical and drug intervention for early stage melanoma patients. 1. A study published in Journal for ImmunoTherapy of Cancer was led by MIA & had numerous MIA authors incl Assoc Prof Alex

The working party updating the 'Clinical Practice Guidelines for the Diagnosis and Management of Melanoma' is now seeking comment from clinicians and the community. This year’s #MelanomaMarch campaign, which was the largest ever, raised vital funds to support the updating of

MIA was pleased to participate in the Australasian Skin Cancer Congress (#ASCC) on the Gold Coast from 16-18 May. The theme was #PartnersInPrevention, highlighting how clinicians can work together in the prevention, diagnosis, & treatment of skin cancer. During the congress three

On International Clinical Trials Day – 20th May 2025, we celebrated the extraordinary patients who contribute to research & clinical trials. We are grateful for their quiet courage, often in the face of limited treatment options, to choose to participate in clinical trials across

It was an honour to deliver the Opening Keynote Address at the Asia-Pacific Vaccine and Immunotherapy Congress (APVIC) in Brisbane this week. I spoke about Therapeutic Cancer Vaccine development and Immunotherapies - Melanoma is the ‘paradigm shifter’ in cancer drug development.

Our MIA research and clinical teams have been at the forefront of global melanoma advances which have made the once incurable, curable. Critical to this is our ‘bench to bedside’ research model. Please donate this tax-time to help us continue this cycle and ultimately save

MIA clinicians and researchers are in Chicago for #ASCO25, sharing latest research and clinical trial results with international colleagues. MIA’s delegation is led by Medical Director Prof Georgina Long AO who will deliver a prestigious oral presentation on results of an

The melanoma & skin cancer poster session has opened at #ASCO25 in Chicago, featuring 11 poster presentations involving MIA researchers. A/Prof Ines Pires da Silva led three projects being presented as posters at ASCO, one relating to predicting response to neoadjuvant

Advances in melanoma treatment have made the once incurable, curable. But why do some advanced melanoma patients still not respond to these treatments? These are research questions, arising in our clinics, that we are desperately working to answer. Please donate this tax-time to

PROF LONG PRESENTS ORAL AT ASCO At the American Society of Clinical Oncology (#ASCO25) Annual Meeting in Chicago, MIA Medical Director Professor Georgina Long AO (Bluesky @gvlongphdmd) AO has delivered a prestigious oral on a post-surgery (adjuvant) immunotherapy clinical trial. The RELATIVITY-098 trial assessed

PROMISING RESULTS FOR STAGE IIB/C PRESENTED AT ASCO. MIA surgeon, Assoc Prof Alex van Akkooi, has delivered an oral abstract at #ASCO25 on early results from the COLUMBUS-AD trial. The trial, which was run through the European Organisation for Research and Treatment of Cancer

Join us for a special evening in Hobart with four-time Olympic gold medallist & melanoma survivor #CateCampbell. Hosted by MIA & #StLukesHealth, this one-hour event offers the chance to hear Cate’s story— her #melanoma diagnosis & how it changed her perspective on health, sun

Prestigious NHMRC grants have been awarded for two #clinicaltrials aiming to improve the accuracy of skin cancer diagnosis in Australia. One of the clinical trials is “Skin cancer UNCUT: Beyond 'if in doubt, cut it out'”, a randomised controlled trial of adjunctive in vivo

Featured on the front page of The The Australian today: World-first clinical trials led by Melanoma Institute Australia (MIA) in conjunction with colleagues in the Netherlands found giving neoadjuvant (before surgery) combination immunotherapy was far more effective than the

Thanks to the NADINA clinical trial, led by MIA & colleagues in the Netherlands, neoadjuvant (before surgery) combination immunotherapy has been proven to be far more effective for the treatment of Stage III melanoma than the current standard post-surgery approach. As a result,

Breakthrough melanoma treatment approved to be listed on PBS. The neoadjuvant (pre-surgery) use of combination immunotherapy as frontline treatment for high risk Stage III melanoma has been approved by the Pharmaceutical Benefits Advisory Committee (#PBAC) and will soon be listed

Meet Jesse Brown, a PhD student at Melanoma Institute Australia, working at Macquarie University. We asked Jesse the pressing questions we wanted to know about the life of a melanoma researcher, like... ❓How did you get into melanoma research? ❓Can you summarise your latest

Is sentinel node biopsy still recommended in 2025, especially with the rise of neoadjuvant immunotherapy? In our latest episode of the 'Melanoma Insights for Professionals' podcast, experts from MIA unpack the latest evidence, and discuss clinical decision-making and evolving

Thanks to our research & new treatments, incl immunotherapy, more than 55% of advanced melanoma patients are effectively cured. Our focus is now on the remaining 45% of advanced melanoma patients who either don’t respond to, or develop resistance to, the same treatments that

MIA's new 'Neoadjuvant immunotherapy for melanoma' patient information leaflet is available on our website! #NeoadjuvantImmunotherapy has proven to be a life-saving new treatment for #melanoma. ‘Neoadjuvant therapy’ refers to any treatment given before the main treatment (which